Brandon Capital – Myricx Bio acquisition by Novartis – deal closes
September 7, 2026
On August 28, 2026, Myricx Bio became an indirect, wholly owned subsidiary of Novartis AG.
Myricx Bio has developed a promising N-myristoyltransferase inhibitor (NMTi) payload platform with a differentiated mechanism that could broaden the use of ADCs across multiple tumor settings. Its NMTi payloads are designed to disrupt critical processes that cancer cells rely on.
By combining Novartis oncology expertise with Myricx Bio’s novel ADC assets and platform with broad potential across multiple solid tumour types, the acquisition provides the best opportunity to advance NMTi-ADCs for more effective and better tolerated therapeutic options for cancer patients.
